[
  {
    "sentence": "Figure 1 demonstrates a conceptual model of the ARIMA method.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Months when the observed rates exceeded the 95% prediction interval (PI) surrounding the forecasted estimates were deemed to have been statistically significantly affected by the pandemic (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In-Person Visit Rates\nEarly pandemic months experienced significant reductions in in-person visit rates for oral therapy (March to May 2020) and outpatient infusions (April to May 2020) subgroups over all diseases combined (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The vertical blue dotted lines indicate the onset of the COVID-19 pandemic; shaded areas indicate the 95% prediction interval.When stratified by disease, patients with multiple myeloma had significant reductions within each treatment type (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "During this period, in-person visit rates returned to close to nonpandemic rates for many diseases and treatment types (Figure 2 and eTables 4 and 5 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This trend persisted across all treatment types (Figure 2 and eTable 6 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 1 demonstrates a conceptual model of the ARIMA method.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Months when the observed rates exceeded the 95% prediction interval (PI) surrounding the forecasted estimates were deemed to have been statistically significantly affected by the pandemic (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In-Person Visit Rates\nEarly pandemic months experienced significant reductions in in-person visit rates for oral therapy (March to May 2020) and outpatient infusions (April to May 2020) subgroups over all diseases combined (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The vertical blue dotted lines indicate the onset of the COVID-19 pandemic; shaded areas indicate the 95% prediction interval.When stratified by disease, patients with multiple myeloma had significant reductions within each treatment type (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "During this period, in-person visit rates returned to close to nonpandemic rates for many diseases and treatment types (Figure 2 and eTables 4 and 5 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This trend persisted across all treatment types (Figure 2 and eTable 6 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 1 demonstrates a conceptual model of the ARIMA method.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Months when the observed rates exceeded the 95% prediction interval (PI) surrounding the forecasted estimates were deemed to have been statistically significantly affected by the pandemic (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In-Person Visit Rates\nEarly pandemic months experienced significant reductions in in-person visit rates for oral therapy (March to May 2020) and outpatient infusions (April to May 2020) subgroups over all diseases combined (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The vertical blue dotted lines indicate the onset of the COVID-19 pandemic; shaded areas indicate the 95% prediction interval.When stratified by disease, patients with multiple myeloma had significant reductions within each treatment type (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "During this period, in-person visit rates returned to close to nonpandemic rates for many diseases and treatment types (Figure 2 and eTables 4 and 5 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This trend persisted across all treatment types (Figure 2 and eTable 6 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 1 demonstrates a conceptual model of the ARIMA method.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Months when the observed rates exceeded the 95% prediction interval (PI) surrounding the forecasted estimates were deemed to have been statistically significantly affected by the pandemic (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In-Person Visit Rates\nEarly pandemic months experienced significant reductions in in-person visit rates for oral therapy (March to May 2020) and outpatient infusions (April to May 2020) subgroups over all diseases combined (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The vertical blue dotted lines indicate the onset of the COVID-19 pandemic; shaded areas indicate the 95% prediction interval.When stratified by disease, patients with multiple myeloma had significant reductions within each treatment type (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "During this period, in-person visit rates returned to close to nonpandemic rates for many diseases and treatment types (Figure 2 and eTables 4 and 5 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This trend persisted across all treatment types (Figure 2 and eTable 6 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 1 demonstrates a conceptual model of the ARIMA method.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Months when the observed rates exceeded the 95% prediction interval (PI) surrounding the forecasted estimates were deemed to have been statistically significantly affected by the pandemic (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In-Person Visit Rates\nEarly pandemic months experienced significant reductions in in-person visit rates for oral therapy (March to May 2020) and outpatient infusions (April to May 2020) subgroups over all diseases combined (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The vertical blue dotted lines indicate the onset of the COVID-19 pandemic; shaded areas indicate the 95% prediction interval.When stratified by disease, patients with multiple myeloma had significant reductions within each treatment type (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "During this period, in-person visit rates returned to close to nonpandemic rates for many diseases and treatment types (Figure 2 and eTables 4 and 5 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This trend persisted across all treatment types (Figure 2 and eTable 6 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 1 demonstrates a conceptual model of the ARIMA method.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Months when the observed rates exceeded the 95% prediction interval (PI) surrounding the forecasted estimates were deemed to have been statistically significantly affected by the pandemic (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In-Person Visit Rates\nEarly pandemic months experienced significant reductions in in-person visit rates for oral therapy (March to May 2020) and outpatient infusions (April to May 2020) subgroups over all diseases combined (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The vertical blue dotted lines indicate the onset of the COVID-19 pandemic; shaded areas indicate the 95% prediction interval.When stratified by disease, patients with multiple myeloma had significant reductions within each treatment type (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "During this period, in-person visit rates returned to close to nonpandemic rates for many diseases and treatment types (Figure 2 and eTables 4 and 5 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This trend persisted across all treatment types (Figure 2 and eTable 6 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 1 demonstrates a conceptual model of the ARIMA method.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Months when the observed rates exceeded the 95% prediction interval (PI) surrounding the forecasted estimates were deemed to have been statistically significantly affected by the pandemic (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In-Person Visit Rates\nEarly pandemic months experienced significant reductions in in-person visit rates for oral therapy (March to May 2020) and outpatient infusions (April to May 2020) subgroups over all diseases combined (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The vertical blue dotted lines indicate the onset of the COVID-19 pandemic; shaded areas indicate the 95% prediction interval.When stratified by disease, patients with multiple myeloma had significant reductions within each treatment type (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "During this period, in-person visit rates returned to close to nonpandemic rates for many diseases and treatment types (Figure 2 and eTables 4 and 5 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This trend persisted across all treatment types (Figure 2 and eTable 6 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 1 demonstrates a conceptual model of the ARIMA method.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Months when the observed rates exceeded the 95% prediction interval (PI) surrounding the forecasted estimates were deemed to have been statistically significantly affected by the pandemic (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In-Person Visit Rates\nEarly pandemic months experienced significant reductions in in-person visit rates for oral therapy (March to May 2020) and outpatient infusions (April to May 2020) subgroups over all diseases combined (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The vertical blue dotted lines indicate the onset of the COVID-19 pandemic; shaded areas indicate the 95% prediction interval.When stratified by disease, patients with multiple myeloma had significant reductions within each treatment type (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "During this period, in-person visit rates returned to close to nonpandemic rates for many diseases and treatment types (Figure 2 and eTables 4 and 5 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This trend persisted across all treatment types (Figure 2 and eTable 6 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 1 demonstrates a conceptual model of the ARIMA method.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Months when the observed rates exceeded the 95% prediction interval (PI) surrounding the forecasted estimates were deemed to have been statistically significantly affected by the pandemic (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1 demonstrates a conceptual model of the ARIMA method.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Months when the observed rates exceeded the 95% prediction interval (PI) surrounding the forecasted estimates were deemed to have been statistically significantly affected by the pandemic (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1 demonstrates a conceptual model of the ARIMA method.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Months when the observed rates exceeded the 95% prediction interval (PI) surrounding the forecasted estimates were deemed to have been statistically significantly affected by the pandemic (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1 demonstrates a conceptual model of the ARIMA method.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Months when the observed rates exceeded the 95% prediction interval (PI) surrounding the forecasted estimates were deemed to have been statistically significantly affected by the pandemic (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In-Person Visit Rates\nEarly pandemic months experienced significant reductions in in-person visit rates for oral therapy (March to May 2020) and outpatient infusions (April to May 2020) subgroups over all diseases combined (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The vertical blue dotted lines indicate the onset of the COVID-19 pandemic; shaded areas indicate the 95% prediction interval.When stratified by disease, patients with multiple myeloma had significant reductions within each treatment type (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "During this period, in-person visit rates returned to close to nonpandemic rates for many diseases and treatment types (Figure 2 and eTables 4 and 5 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This trend persisted across all treatment types (Figure 2 and eTable 6 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In-Person Visit Rates\nEarly pandemic months experienced significant reductions in in-person visit rates for oral therapy (March to May 2020) and outpatient infusions (April to May 2020) subgroups over all diseases combined (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The vertical blue dotted lines indicate the onset of the COVID-19 pandemic; shaded areas indicate the 95% prediction interval.When stratified by disease, patients with multiple myeloma had significant reductions within each treatment type (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "During this period, in-person visit rates returned to close to nonpandemic rates for many diseases and treatment types (Figure 2 and eTables 4 and 5 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Early pandemic months experienced significant reductions in in-person visit rates for oral therapy (March to May 2020) and outpatient infusions (April to May 2020) subgroups over all diseases combined (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "When stratified by disease, patients with multiple myeloma had significant reductions within each treatment type (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "During this period, in-person visit rates returned to close to nonpandemic rates for many diseases and treatment types (Figure 2 and eTables 4 and 5 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This trend persisted across all treatment types (Figure 2 and eTable 6 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This trend persisted across all treatment types (Figure 2 and eTable 6 in Supplement 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  }
]